You are viewing the site in preview mode

Skip to main content

Table 1 Mean plasma SuPAR levels at each timepoint

From: Plasma SuPAR and therapeutic response to erenumab in migraine: a REFORM study

 

Baseline

Week 24

Week 48

 

n

Mean (SD), ng/mL

n

Mean (SD), ng/mL

n

Mean (SD), ng/mL

Total population

      

Migraine (N = 623)

622

2.59 (0.69)

587

2.60 (0.67)

233

2.66 (0.65)

Responders* (n = 282)

282

2.54 (0.62)

276

2.56 (0.64)

97

2.52 (0.52)‡

Non-responders* (n = 259)

258

2.62 (0.72)

246

2.62 (0.65)

118

2.75 (0.69)†,‡

Migraine with aura subgroup

      

Migraine (n = 183)

182

2.70 (0.76)†

173

2.76 (0.73)†

67

2.85 (0.79)†

Responders* (n = 81)

81

2.62 (0.72)

79

2.65 (0.61)

28

2.57 (0.63)

Non-responders* (n = 77)

76

2.80 (0.83)†

72

2.76 (0.78)†

36

3.05 (0.82)†

Healthy controls

      

Healthy controls (n = 154)

154

2.44 (0.56)†

-

-

-

-

  1. Abbreviations: MMDs, monthly migraine days; SD, standard deviation; suPAR, soluble urokinase-type plasminogen activator receptor
  2. Symbols:
  3. *, Responders were participants with a ≥ 50% reduction in MMDs, while non-responders experienced < 50% reduction in MMDs
  4. †, statistically significant difference between participants with migraine and healthy controls (p < 0.05)
  5. ‡, statistically significant difference between responders and non-responders (p < 0.05)
  6. Estimates with 95% confidence intervals and p-values are available in Supplementary Table S8 and S14